Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

Executive Summary

A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.

Advertisement

Related Content

Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy
Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee
FDA Accelerates Inspection Process With New Concept Of Operations
Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade
Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar
Keeping Track: Lower Doses Of Narcan, Linzess Approved; US FDA Receives Actemra, Ryanodex, Dextenza Submissions
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel